72 results about "Cancer genes" patented technology

A reliable and highly sensitive method is provided for detecting methylation status of CpG-containing nucleic acids by nucleic acid amplification and melting curve analysis of amplification products. The methods and compositions employs a novel design of primers. CpG-containing methylation-independent oligonucleotide primers, wherein both unmethylated and methylated alleles of a CpG-containing nucleic acid can be detected by use of only one set of primers after the CpG-containing nucleic acid has been subjected to cytosine to thymine conversion of unmethylated Cytosine. The method is useful for detection of methylation status in for example cancer genes and other disease related genes, wherein methylation influences gene expression.

The invention relates to the field of biotechnology and aims to provide multiple primers and probes for detecting mutation of a cancer gene BRAFV600E. The primers and probes provided by the invention respectively comprise a mutation specific forward primer, a mutation non-specific forward primer, universal reverse primers and universal probes shown in SEQ NO.1-11. The detection sensitivity of themutation specific primer and probe provided by the invention can reach 500 copies/ml, thus the sensitivity is good. If a sample does not contain the cancer gene BRAFV600E, the ct value of the amplification curve of the sample is greater than or equal to 36, and the specificity is strong. Because the mutation non-specific primer is simultaneously designed in the invention to be used for detecting the total template quantity of samples, the false negative result is avoided and the quality control is convenient.

Gene probes for specific regions of chromosomes 1, 3, 9, 10 and 17 are now shown to be useful in the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, to determine susceptibility to the development of smoking related cancers, to predict cancer progression and treatment efficacy, and to rule out other diseases.

The invention relates to the gene therapeutic treatment of cancer using co-expressed nucleic acids encoding US28 and a G-protein. e.g. GNA-13, or functional fragments thereof, or using nucleic acids encoding fusion polypeptides of US28 and a G-protein or functional fragments thereof. The pharmaceutical compositions according to the invention are used in the treatment of cancer patients to induce apoptosis in tumor cells.

Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.

The present invention relates to the identification of various prognostic factors that predict response in patients with hyperproliferative disease such as cancer to gene therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy. Also described are methods of treatment for Li Fraumeni syndrome, and for assessing anti-cancer gene therapy using PET scans.

The invention relates to a prostate related cancer gene information collection and analysis method. The invention provides a prostate related cancer gene information collection and analysis system. Through collecting all the data related to the prostate cancer in the existing database, a bioinformatics method is utilized to carry out confluence analysis on the prostate cancer mRNA and miRNA high-throughput transcriptome data, and a prostate cancer diagnostic marker suitable for clinic application is obtained on the basis of large-sample big data processing.

The invention discloses PVT1 siRNA-1055 for inhibiting blood tumor cell proliferation and an application thereof and relates to the fields of siRNA and application thereof. The PVT1 siRNA-1055 in the invention can high-effectively inhibit expression of PVT1 and effectively inhibit proliferation of the blood tumor cells, and has important significance on development of novel anti-blood tumor gene medicines and improvement of therapy effect of blood tumors. As deterioration of living environment of human, morbidity and mortality of blood tumor (such as leukemia and lymphoma) are higher and higher, wherein the blood tumor has become one of main neoplastic diseases that influence health and life of people. Almost all blood tumors have PVT1 expression increase, wherein the PVT1 has the functions as a cancer gene, so that targeted PVT1 therapy has a universal significance, is suitable for almost all blood tumors, and has a huge market potential.

The present invention discloses an approximation spectral clustering algorithm based method for predicting cancer metastasis and recurrence. The method is characterized by comprising: based on an approximation spectral clustering algorithm, constructing a cancer metastasis and recurrence prediction model by using cancer gene expression profile data as a training set sample; and using the prediction model for a test of a cancer metastasis and recurrence independent testing sample set, and classifying cancer patients into two types of patients: a metastasis and recurrence type and a non metastasis and recurrence type. According to the method provided by the present invention, it is predicted whether the cancer patients will be subjected to metastasis and recurrence, so that subsequent treatment of the cancer patients is more targeted.

The invention discloses a real-time fluorescent quantitative PCR detection method of human breast cancer genotypes. The method comprises the following steps: ERa (SEQID9), PR(SEQID10) and HER-2(SEQID11) of the human breast cancer gene are taken as augmented target gene sequences, 18SrRNA(SEQID12) is taken as an internal control gene, specific primers are designed corresponding to the ERa gene, the PR gene, the HER-2 gene and the 18SrRNA gene respectively, CT values of a sample to be detected and a control sample are detected through adopting the real-time fluorescent quantitative PCR method, and the target gene expression level is calculated; the target gene expression level is analyzed through the delta delta CT method, the target gene expression level equals to 2<delta delta CT>, wherein delta delta CT equals to (CT, target minus CT, 18S)(detected) minus (CT, target minus CT, 18S)(control); when the target gene expression level is less than or equal to 1, the ERa gene, the PR gene and the HER-2 gene are subject to negative typing; and when the target gene expression level is more than 1, the ERa gene, the PR gene and the HER-2 gene are subject to positive typing. The invention has the advantages of simplicity and convenience in operation, high detection sensitivity, short detection time, good specificity and repetitiveness, accurate and reliable results and qualitative and quantitative detection, can be used for genotype identification of common populations or patients with breast cancer, provides an important theoretical index on personalized for the patients with breast cancer to personally take medicine, has significance for prognosis of the patients with breast cancer, and has stronger popularization and practicability.

The invention provides high throughput screening systems and in vivo methods for high throughput screening of cancer genes. The invention also is applicable to the discovery of therapeutic agents that block tumor growth and metastasis. The invention further provides kits and compositions to perform such assays.

A gene expression signature of colon cancer, microarrays including them and methods of using the colon gene expression signature are provided. The gene expression signature is especially useful for determining the prognosis of a patient diagnosed with colon cancer, such as stage II colon cancer. The gene signature described herein is also useful for determining effectiveness of surgical resection with or without adjuvant chemotherapy, and determining possibility of cancer recurrence in patients with colon cancer.

Genes for thirteen DNA damage repair or DNA damage response enzymes can be epigenetically silenced in cancers. The silencing of nucleic acids encoding a DNA repair or DNA damage response enzyme can be used prognostically and for selecting treatments that are well tailored for an individual patient. Combinations of these markers can also be used to provide prognostic information. Kits for testing epigenetic silencing can be used to determine a prognosis or a therapeutic regimen.

The present invention features transgenic non-human mammalian animals being genetically modified to develop cancer. The invention also relates to methods for identifying genes or genetic elements that are potentially related to human cancers using an chromosomally unstable animal model. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.

The invention provides a method for inhibiting proliferation and inducing apoptosis of cancer cells, which inhibits the proliferation and induces the apoptosis of the cancer cells by using the siRNA of the targeted transportation gene of a protamine polypeptide fusion protein which is a single-chain fragment antibody. The invention also provides the protamine polypeptide fusion protein and a medicament for inhibiting the proliferation and inducing the apoptosis of the cancer cells. The fusion protein can inhibit the proliferation and induce the apoptosis of the cancer cells. The medicament contains an effective amount of the fusion protein and the siRNA of a tumor gene. In the invention, the siRNA of the tumor gene can be transferred to a specific cell population needing gene silencing to improve treatment effect, the RNAi has high pertinence, and the gene silencing effect is improved with the reduction in side effects. It is expected to block the expression of a cancer gene on a genetic level, destruct the proliferation of the cancer cells and a transfer signal transmission mechanism radically, and improve the sensitivity of the cancer cells to chemotherapeutics.

The invention discloses a pharmaceutical composition containing medicinal calcium salt for early preventing colorectal adenoma or colorectal cancer. The pharmaceutical composition contains sodium butyrate and medicinal calcium salt, wherein the mass ratio of the sodium butyrate to elemental calcium in the pharmaceutical composition is (2.47-4.95):1. The pharmaceutical composition disclosed by the invention can reduce cancer genes related to the colorectal cancer and can increase related cancer suppressor genes and signal passages to suppress colorectal cancer cell proliferation and migration capabilities and retard cell growth cycle, thereby achieving the purposes of suppressing the occurrence of the colorectal cancer, lowering the incidence rate of the colorectal cancer of mice, and reducing the tumor volume.

The diagnosis method combining PCR and short segment DNA sequencing relates to a biological detection method, specially it is applicable to the research fields of antenated diagnosis of genetic disease, detection of pathogenic pathogen, detection and diagnosis of cancer gene, genetic fingerprinting, individual identification and offspring-parent relationship determination, animal and plant quaretine and biological emdicine, etc. Said invention uses two ends of micro target gene or two-side known nucleotide sequences to design a pair of primers, and uses DNA to be identified as template to make PCR amplification.

The present invention relates to an oncolytic adenovirus simultaneously expressing interleukin-12 and shVEGF, and an antitumor immunity enhancing composition and an anticancer effect promoting composition each containing the same. The present inventors verified that the simultaneous occurrence of VEGF inhibition and IL-12 expression induced the recovery of an immune function and the promotion of an anticancer effect in an immunological mouse melanoma or kidney cancer model. Especially, the applicability of a gene carrier simultaneously expressing IL-2 and shVEGF in the cancer gene therapy was first established by disclosing that the increased anticancer effect is involved in an increase in anticancer immunity, an increase in TH 1 cytokine, and the prevention of tumor induced thymic atrophy.

A recombinant adenovirus expressing a streptolysin O (SLO) protein comprising a SLO gene; a promoter operably linked to the SLO gene; a polyadenylation signal sequence; and an adenovirus genome lacking E1 gene effectively kills a cancer cell by expressing a pore-forming toxin, SLO protein, and, therefore, is useful for the suicide cancer gene therapy.

The invention discloses an important gene enrichment method used for individual cancer diagnosis and treatment. A combination of common cancer genes of Chinese patients is established, an enrichment scheme is designed according to the mutation characteristics of the genes of Chinese patients to achieve efficient targeting enrichment of important cancer genes, and the sequencing flux of above 20000 genes reduces to below 200 genes, so the sequencing cost is substantially reduced. The method containing the enrichment scheme of gene transposition and other special mutations can detect the mutation which cannot be detected by an exon and is important for diagnosis and treatment.

The invention relates to the application of FHL 1 in preparing medicament for treating tumour, in particular to the application of the FHL 1 in preparing the medicament for regulating the expression of cancer genes and/or cancer suppressor genes in cells of mammals and the application of the FHL 1 in preparing the medicament for restraining the growth of tumour cells of the mammals. The inventionalso relates to an expression carrier containing a nucleotide sequence for coding the FHL 1, the application of the expression carrier in preparing the medicament for regulating the expression of thecancer genes and/or the cancer suppressor genes in the cells of the mammals and the application of the expression carrier in preparing the medicament for restraining the growth of the tumour cells ofthe mammals. The expression carrier can effectively suppress the growth of multiple human tumour cells and restrain the growth of the human tumour cells by regulating the expression of the cancer genes and the cancer suppressor genes.